MX2016001422A - Composicion farmaceutica de fingolimod. - Google Patents

Composicion farmaceutica de fingolimod.

Info

Publication number
MX2016001422A
MX2016001422A MX2016001422A MX2016001422A MX2016001422A MX 2016001422 A MX2016001422 A MX 2016001422A MX 2016001422 A MX2016001422 A MX 2016001422A MX 2016001422 A MX2016001422 A MX 2016001422A MX 2016001422 A MX2016001422 A MX 2016001422A
Authority
MX
Mexico
Prior art keywords
fingolimod
pharmaceutical compositions
preparation
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
MX2016001422A
Other languages
English (en)
Inventor
Kumar Alluri Pavan
Chandra Bose Mylamala Subhash
Dontika Nagaraju
Thummisetty Mastanaiah
Kandarapu Raghupathi
S Rudraraju Varma
Original Assignee
Aizant Drug Res Solutions Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52431073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016001422(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aizant Drug Res Solutions Pvt Ltd filed Critical Aizant Drug Res Solutions Pvt Ltd
Publication of MX2016001422A publication Critical patent/MX2016001422A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica estable que contiene fingolimod, una sal farmacéuticamente aceptable de la misma o un derivado de fosfato como ingrediente activo y su preparación.
MX2016001422A 2013-07-29 2013-12-10 Composicion farmaceutica de fingolimod. MX2016001422A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3368CH2013 2013-07-29
PCT/IB2013/060770 WO2015015254A1 (en) 2013-07-29 2013-12-10 Pharmaceutical compositions of fingolimod

Publications (1)

Publication Number Publication Date
MX2016001422A true MX2016001422A (es) 2016-10-05

Family

ID=52431073

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001422A MX2016001422A (es) 2013-07-29 2013-12-10 Composicion farmaceutica de fingolimod.

Country Status (6)

Country Link
US (1) US20160128951A1 (es)
EP (1) EP3027174B1 (es)
JP (1) JP6316422B2 (es)
CA (1) CA2920758A1 (es)
MX (1) MX2016001422A (es)
WO (1) WO2015015254A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CN106075456A (zh) * 2015-04-27 2016-11-09 南京圣和药业股份有限公司 一种含乐伐替尼的药物组合物及其应用
EA201890477A1 (ru) * 2015-09-18 2018-08-31 Сановел Иладж Санайи Ве Тиджарет А.С. Инкапсулированная композиция финголимода
MX2018004021A (es) * 2015-10-02 2018-09-11 Mylan Inc Formulaciones estables de fingolimod.
CN109265679B (zh) * 2018-08-20 2021-02-05 暨南大学 一种聚(谷氨酸-胆碱磷酸)及其作为疫苗免疫佐剂的应用
WO2021140424A1 (en) * 2020-01-06 2021-07-15 Shilpa Medicare Limited Fingolimod extended release injectable suspension
JP7342780B2 (ja) 2020-05-01 2023-09-12 住友電気工業株式会社 ガラス母材の製造装置
WO2022253077A1 (zh) * 2021-05-31 2022-12-08 上海博志研新药物技术有限公司 芬戈莫德药用盐、制备方法、含其的药物组合物及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172711T1 (de) 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
JP4153563B2 (ja) * 1997-02-27 2008-09-24 ノバルティス アーゲー 医薬組成物
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
EP2316431B1 (en) 2003-04-08 2015-09-30 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
PL1773307T3 (pl) 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
PL3103448T3 (pl) 2006-09-26 2019-12-31 Novartis Ag Kompozycje farmaceutyczne zawierające modulator S1P
PT2952177T (pt) 2007-10-12 2021-04-26 Novartis Ag Composições compreendendo moduladores do recetor de fosfato de esfingosina 1 (s1p)
RU2562571C2 (ru) * 2008-06-20 2015-09-10 Новартис Аг Педиатрические композиции для лечения рассеянного склероза
CA2743232C (en) * 2008-11-11 2015-12-29 Novartis Ag Crystalline forms of fingolimod hcl
DK3536333T3 (da) * 2010-01-04 2022-10-24 Mapi Pharma Ltd Depotsystem der omfatter glatirameracetat
EP2560621A1 (en) 2010-04-22 2013-02-27 Ratiopharm GmbH Fingolimod in the form of a solid solution
WO2011131368A2 (en) 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
CA2797551A1 (en) 2010-04-22 2011-10-27 Ratiopharm Gmbh Melt-granulated fingolimod
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EP2699317B1 (en) * 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
US9186333B2 (en) 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod

Also Published As

Publication number Publication date
US20160128951A1 (en) 2016-05-12
WO2015015254A1 (en) 2015-02-05
CA2920758A1 (en) 2015-02-05
EP3027174A1 (en) 2016-06-08
JP6316422B2 (ja) 2018-04-25
JP2016525568A (ja) 2016-08-25
EP3027174B1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2013001677A (es) Formulaciones estables de linaclotida.
PH12015502013B1 (en) Pharmaceutical composition of s-ketamine hydrochloride
PH12015501957A1 (en) Pharmaceutical composition of s-ketamine hydrochloride
PH12015501096A1 (en) Composition for immediate and extended release
EP3613419A4 (en) PHARMACEUTICAL COMPOSITION WITH INDIRUBY DERIVATIVE AS THE ACTIVE SUBSTANCE
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
EP2871187A4 (en) NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT
WO2014166836A8 (en) Growth hormone compound formulation
PH12019500024A1 (en) Pharmaceutical compositions
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
IN2013MU02442A (es)
EA201491477A1 (ru) Фармацевтические составы, содержащие флупиртин
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου